Posted: August 30, 2014 at 12:40 pm
Tues 26th Aug: ALS Discussion, Dave Style?
Considering that it #39;s Tuesday Dave once again tries and fails to appear intellectual, informative and generally not a moron as he tip-toes around a bit of a controversial topic in Stem Cell...
By: NerdFightersInfo
Posted: August 30, 2014 at 5:53 am
PUBLIC RELEASE DATE:
29-Aug-2014
Contact: Kris Kitto kris@morethanpr.com 303-320-7790 The Bawmann Group
AURORA, Colo. (Sept. 2, 2014) A team of scientists from the University of Colorado School of Medicine has reported the breakthrough discovery of a process to expand production of stem cells used to treat cancer patients. These findings could have implications that extend beyond cancer, including treatments for inborn immunodeficiency and metabolic conditions and autoimmune diseases.
In an article published Aug. 29 in PLOS ONE, researchers from the Charles C. Gates Center for Regenerative Medicine and Stem Cell Biology and Taiga Biotechnologies, Inc. said they have uncovered the keys to the molecular code that appear to regulate the ability of blood stem cells to reproduce and retain their stem-like characteristics.
The team developed protein products that can be directly administered to blood stem cells to encourage them to multiply without permanent genetic modifications.
"Use of stem cells to treat cancer patients who face bone marrow transplants has been a common practice for four decades," said Yosef Refaeli, Ph.D., an associate dermatology professor and one of the study's lead scientists. "The biggest challenge, however, has been finding adequate supplies of stem cells that help patients fight infection after the procedure."
Gates Stem Cell Center Director Dennis Roop, Ph.D., recognized the magnitude of the team's work.
"Researchers have long attempted to increase the number of blood stem cells in a lab," Roop said. "Most of those approaches have been limited by the nature of the resulting cells or the inadequate number of cells produced."
The technology described in the PLOS ONE article has worked with blood stem cells obtained from cord blood, adult bone marrow or peripheral blood from adults.
Go here to see the original:
CU scientists' discovery could lead to new cancer treatment
Posted: August 30, 2014 at 5:53 am
Burnt Hills, NY (PRWEB) August 29, 2014
Local veterinarian, Dr. Keith Clement, and his team at Burnt Hills Veterinary Hospital are seeking candidates to participate in an investigational study of donor stem cells for dogs with osteoarthritis. The ultimate goal of this study is to determine if a single injection of donor stem cells into one or two arthritically affected joints can help reduce pain and inflammation in the treated joints.
Candidates for the current investigational study must be older than nine months, weigh more than five and a half pounds, have osteoarthritis of only one or two leg joints, have had pain or lameness for at least three months, and must not have cancer. Joints that will be included in the study and injected under anesthesia include hips, stifles, shoulders, and elbows. Dogs that may be considered must be in good health and undergo a diagnostic work up before qualifying for the study. Dogs that qualify for the study may not have had previous stem cell therapy of any kind.
In 2008, Dr. Clement was credentialed with Vet-Stem, Inc. in Regenerative Veterinary Medicine for arthritis, ligament and tendon injuries, and joint issues with stem cell therapy. To date he has treated over 80 patients. In May 2011 Dr. Clement presented a paper at the 2nd Annual North American Veterinary Regenerative Medicine Association Conference and November 2011 he spoke on stem cell therapy at the Illinois Veterinary Medical Association Conference.
For information about the study, Dr. Clement can be reached at 518-399-5213.
About Vet-Stem, Inc. Since its formation in 2002, Vet-Stem, Inc. has endeavored to improve the lives of animals through regenerative medicine. As the first company in the United States to provide an adipose-derived stem cell service to veterinarians for their patients, Vet-Stem pioneered the use of regenerative stem cells for horses, dogs, and cats. In 2004 the first horse was treated with Vet-Stem Regenerative Cell Therapy. Ten years later Vet-Stem celebrated its 10,000th animal treated. As animal advocates, veterinarians, veterinary technicians, and cell biologists, the team at Vet-Stem tasks themselves with the responsibility of discovering, refining, and bringing to market innovative medical therapies that utilize the bodys own healing and regenerative cells.
Follow this link:
Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis
Posted: August 30, 2014 at 5:48 am
Boston, MA (PRWEB) August 29, 2014
A major challenge before new biotechnology start-up companies, especially ones in the biotech start-up dense realm of Boston-Cambridge, is gaining visibility that can lead to important strategic alliances and able investors. James Sherley, the Director of Bostons Adult Stem Cell Technology Center, LLC (ASCTC), has made increasing the local and national visibility of his company an important priority since he started the company in September 2013.
In addition to a social media marketing campaign launched earlier in July of this year, Director Sherley has targeted research and development conferences both nationally and internationally to increase industry awareness of ASCTCs unique portfolio of intellectual property available for licensing and its current commercial development targets. The company is focused on producing two products to address two important needs in drug development and regenerative medicine, respectively, that it is uniquely positioned to address.
ASCTCs most advanced product is an assay that can detect, very early in the drug development pipeline, drug candidates that will ultimately fail because of their toxicity to tissue stem cells. ASCTC developed the new technology in partnership with AlphaSTAR, Corporation, located in Long Beach, California. Currently, such lurking drugs are not detected until after expensive animal testing, more expensive clinical trials, or worse, after marketing. Director Sherley refers to the second product as, A future of pounds and pounds of normal adult tissue stem cells. The company holds a patented technology for mass production of human tissue stem cells. The initial production target is human liver stem cells that can be used to make mature human liver cells for use in drug development and to support liver transplant patients. The company also holds patents for production of pancreatic stem cells and hair follicle stem cells.
The sponsor the 2014 Stem Cells & Regenerative Medicine Conference, in Boston, September 15-16, Terrapinn, Inc., invited ASCTC to attend as a VIP guest. Although ASCTC will not make a formal presentation at this conference, Director Sherley will participate in a roundtable discussion on the topic, Articulating value for up-and-coming regenerative medicine, stem cell and cell-based therapies.
Later in September (22-24), Director Sherley will present one of the selected Next Generation Presentations for new companies at BioPharm America 2014, also taking place in Boston. In addition to the public presentation, ASCTC will also participate in confidential partnering meetings with potential investors and strategic alliance partners arranged by conference organizers.
In October, Director Sherley will present to a primarily academic research audience a more detailed accounting of ASCTCs computer simulation technology for quantifying tissue stem cells in culture. This technology is the basis for the companys new assay for tissue stem cell toxicity. Director Sherley is particularly interested in the response from several experts in tissue stem cell growth dynamics who are invited speakers. The symposium, which will take place at Rhode Island Hospital, a medical affiliate of Brown University in Providence, has the goal of presenting emerging disruptive research in the area of Novel Stem Cells and Vesicles. Director Sherley is a member of the symposium organizing committee. ************************************************************************************************************* The Adult Stem Cell Technology Center, LLC (ASCTC) is a Massachusetts life sciences company established in September 2013. ASCTC Director and founder, James L. Sherley, M.D., Ph.D. is the foremost authority on the unique properties of adult stem cells. The companys patent portfolio contains biotechnologies that solve the two main technical problems production and quantification that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing iPSCs. Currently, ASCTC is employing its technological advantages to pursue commercialization of mass-produced therapeutic human liver cells and facile assays that are early warning systems for drug candidates with catastrophic toxicity due to adverse effects against adult tissue stem cells.
Read more here:
The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences ...
Posted: August 30, 2014 at 5:48 am
Stem Cell Activation Phuket, Thailand: How have the stem cell therapy results been so far
http://www.thanyapurahealth.com/health-services/natural-stem-cell-activationregenerative-therapy/stem-cell-activation-phuket-thailand-how-have-the-stem-cell-therapy-results-been-so-far/ Client...
By: Thanyapura Health Centre
Here is the original post:
Stem Cell Activation Phuket, Thailand: How have the stem cell therapy results been so far - Video
Posted: August 30, 2014 at 5:48 am
Stem Cell Activation Phuket, Thailand: How is your stem cell therapy different
http://www.thanyapurahealth.com/health-services/natural-stem-cell-activationregenerative-therapy/how-is-your-stem-cell-therapy-different/ Thanyapura Health offers natural stem cell activation,...
By: Thanyapura Health Centre
Read this article:
Stem Cell Activation Phuket, Thailand: How is your stem cell therapy different - Video
Posted: August 30, 2014 at 5:48 am
Stem Cell Activation Phuket, Thailand: How have athletes been using stem cell therapy
http://www.thanyapurahealth.com/health-services/natural-stem-cell-activationregenerative-therapy/how-have-athletes-been-using-stem-cell-therapy/ Using stem cell therapy treats body issue e.g....
By: Thanyapura Health Centre
Go here to read the rest:
Stem Cell Activation Phuket, Thailand: How have athletes been using stem cell therapy - Video
Posted: August 30, 2014 at 5:48 am
Stem Cell Activation Phuket: What type of clients have you been seeing for stem cell therapy
http://www.thanyapurahealth.com/health-services/natural-stem-cell-activationregenerative-therapy/what-type-of-clients-have-you-been-seeing-for-stem-cell-therapy/ Wide range of client who has...
By: Thanyapura Health Centre
Link:
Stem Cell Activation Phuket: What type of clients have you been seeing for stem cell therapy - Video
Posted: August 30, 2014 at 5:48 am
Jilly #39;s Miracle post stem cell therapy at Australind Veterinary Hospital
Jilly pain free following stem cell therapy at Australind Veterinary Hospital.
By: AustralindVet
See the original post here:
Jilly's Miracle post stem cell therapy at Australind Veterinary Hospital - Video
Posted: August 30, 2014 at 5:48 am
Boston, MA (PRWEB) August 29, 2014
Due to a misstatement posted by the Family Resource Council (FRC) last week, the Adult Stem Cell Technology Center, LLC (ASCTC) was reported as an entity accepting donations to support stem cell therapy research that might benefit ALS patients. Because of ASCTC's exclusive focus on developing adult stem cells for new stem cell technologies and therapeutic applications, FRC listed ASCTC as one of several alternatives for ALS Ice Bucket Challenge donors who wish not to support research that requires the death of human embryos or fetal abortions.
After authorizing the listing by FRC, ASCTC's Director James Sherley states that he was surprised by suddenly receiving a number of communications from individuals inquiring how to donate to ASCTC. A look at the FRC posting explained the contacts. Inadvertently, ASCTC had been indicated as an agency that received donations for stem cell research. After ASCTC notified FRC staff of the mistake, the posting was immediately corrected. Since the correction, Director Sherley reports that the number of donation contacts has decreased, but not stopped completely.
In addition to the FRC correction, the ASCTC now responds to donation inquiries with the following statement:
Thank you for your interest in donating to ASCTC to support its development efforts in adult stem cell technologies. If your query was motivated by a recent Family Resource Council (FRC) notice, unfortunately, the notice posted by FRC was mistaken in its 'donate' message and did not adequately indicate that ASCTC is a for-profit company. Therefore, there is no means by which to 'donate' to the company. At my request, FRC has now corrected the posting. It is possible to invest in ASCTC commercial development of technologies for producing and quantifying human adult stem cells for drug development and therapeutics. However, this was not the intent of the FRC notice. Its purpose was to make the public aware of all the entities, not-for-profit or for-profit, engaged in developing stem cell technologies, potentially relevant to finding a cure for ALS, that do not use human embryonic stem cells. Please, accept my apologies for the miscommunication; and thank you for your good will in supporting ethical research to help others suffering from devastating illnesses like ALS.
Sincerely,
James L. Sherley Director ASCTC, LLC
Director Sherley observed, The best thing about this unfortunate situation is that I have had the pleasure of communicating with some very caring peopleand that is quite inspiring! ************************************************************************************************************* The Adult Stem Cell Technology Center, LLC (ASCTC) is a Massachusetts life sciences company established in September 2013. ASCTC Director and founder, James L. Sherley, M.D., Ph.D. is the foremost authority on the unique properties of adult stem cells. The companys patent portfolio contains biotechnologies that solve the two main technical problems production and quantification that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing iPSCs. Currently, ASCTC is employing its technological advantages to pursue commercialization of mass-produced therapeutic human liver cells and facile assays that are early warning systems for drug candidates with catastrophic toxicity due to adverse effects against adult tissue stem cells.
Continue reading here:
The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical ...
